TrialResults-center.org

Menu

Brigatinib ALK inhibitors

brigatinib - AP26113

Lung cancer (metastatic)

ALK positive patients: 1 trials - ALTA-1L

brigatinib vs crizotinib

No demonstrated result

Endpoint	TE [95% CI]	p val	I2	n	k	trials
death (overall survival)	no data
progression or death (progression free survival PFS)	no data

TE: treatment effect; CI: confidence interval; k: nulmber of trials; n: total number of patients

Modal title

- About - Browse pathology | treatment - Site map - Credits Made with in Lyon - Contact us - Privacy policy -